Entering text into the input field will update the search result below

OncoSec Medical (ONCS) Presents At LD Micro Virtual Conference 2018 - Slideshow

SA Transcripts profile picture
SA Transcripts

The following slide deck was published by OncoSec Medical Incorporated in conjunction with this event.

Targeting the Tumor

This article was written by

SA Transcripts profile picture
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Recommended For You

Comments (5)

added more today...
ps6772 profile picture
A nice post from JT on Twitter

Roy Baynes puts IL-12 in the front....Perhaps it is the next big thing that Merck is going to push forward.

I also checked Viralytics Melanoma clinical results... Lower than Oncosec...


Roy Baynes, senior vice president and head of global clinical development and the chief medical officer at Merck Research Laboratories

"We have a number of molecules that we have declared publicly," Baynes said. "Many of these are aimed at enhancing the immunogenicity of the cancer" – for example, by pursuing combinations with mechanisms such as the stimulator of interferon genes, or STING, agonist; cytokines, such IL-12; agonist programs such as Toll-like receptors; and agents that target innate immune signaling pathways. Merck also has ongoing efforts targeting indoleamine 23-dioxygenase 1, or IDO-1; cytotoxic T-lymphocyte associated protein 4, or CTLA-4; and lymphocyte-activation gene 3, or LAG-3, among others.

"All of these have the potential to be important, and certainly there is the possibility that certain of these might be explored with new oncolytic viruses," Baynes said. "We have a very rich early pipeline, and we think this is really going to help us bring the benefits of immuno-oncology to a broader array of patients. Obviously, Keytruda is doing amazing things for patients, but there still are a large number of patients who don't respond to Keytruda as monotherapy, so combinations are important to explore."
This company is way under followed Merck will no doubt buy them at some point IMO Long ONCS
Bright spot profile picture
Looks good
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.